Peptide allergen-specific immunotherapy for allergic airway diseases-State of the art

Research output: Contribution to journalReview articlepeer-review

Standard

Peptide allergen-specific immunotherapy for allergic airway diseases-State of the art. / Wraith, David C; Krishna, Mamidipudi T.

In: Clinical and Experimental Allergy , 02.02.2021.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{306c49d10e3a40a2920ed044f32bef8a,
title = "Peptide allergen-specific immunotherapy for allergic airway diseases-State of the art",
abstract = "Allergen-specific immunotherapy (AIT) is the only means of altering the natural immunological course of allergic diseases and achieving long-term remission. Pharmacological measures are able to suppress the immune response and/or ameliorate the symptoms but there is a risk of relapse soon after these measures are withdrawn. Current AIT approaches depend on the administration of intact allergens, often comprising crude extracts of the allergen. We propose that the challenges arising from current approaches, including the risk of serious side-effects, burdensome duration of treatment, poor compliance and high cost, are overcome by application of peptides based on CD4+ T cell epitopes rather than whole allergens. Here we describe evolving approaches, summarize clinical trials involving peptide AIT in allergic rhinitis and asthma, discuss the putative mechanisms involved in their action, address gaps in evidence and propose future directions for research and clinical development.",
keywords = "allergen‐specific immunotherapy, asthma, epitopes, peptides, rhinitis, T cells",
author = "Wraith, {David C} and Krishna, {Mamidipudi T}",
note = "{\textcopyright} 2021 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.",
year = "2021",
month = feb,
day = "2",
doi = "10.1111/cea.13840",
language = "English",
journal = "Clinical and Experimental Allergy ",
issn = "0954-7894",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - Peptide allergen-specific immunotherapy for allergic airway diseases-State of the art

AU - Wraith, David C

AU - Krishna, Mamidipudi T

N1 - © 2021 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.

PY - 2021/2/2

Y1 - 2021/2/2

N2 - Allergen-specific immunotherapy (AIT) is the only means of altering the natural immunological course of allergic diseases and achieving long-term remission. Pharmacological measures are able to suppress the immune response and/or ameliorate the symptoms but there is a risk of relapse soon after these measures are withdrawn. Current AIT approaches depend on the administration of intact allergens, often comprising crude extracts of the allergen. We propose that the challenges arising from current approaches, including the risk of serious side-effects, burdensome duration of treatment, poor compliance and high cost, are overcome by application of peptides based on CD4+ T cell epitopes rather than whole allergens. Here we describe evolving approaches, summarize clinical trials involving peptide AIT in allergic rhinitis and asthma, discuss the putative mechanisms involved in their action, address gaps in evidence and propose future directions for research and clinical development.

AB - Allergen-specific immunotherapy (AIT) is the only means of altering the natural immunological course of allergic diseases and achieving long-term remission. Pharmacological measures are able to suppress the immune response and/or ameliorate the symptoms but there is a risk of relapse soon after these measures are withdrawn. Current AIT approaches depend on the administration of intact allergens, often comprising crude extracts of the allergen. We propose that the challenges arising from current approaches, including the risk of serious side-effects, burdensome duration of treatment, poor compliance and high cost, are overcome by application of peptides based on CD4+ T cell epitopes rather than whole allergens. Here we describe evolving approaches, summarize clinical trials involving peptide AIT in allergic rhinitis and asthma, discuss the putative mechanisms involved in their action, address gaps in evidence and propose future directions for research and clinical development.

KW - allergen‐specific immunotherapy

KW - asthma

KW - epitopes

KW - peptides

KW - rhinitis

KW - T cells

U2 - 10.1111/cea.13840

DO - 10.1111/cea.13840

M3 - Review article

C2 - 33529435

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

ER -